London-based Stress app maker BioBeats has raised $3 million in a funding round led by Oxford Sciences Innovation, White Cloud, and IQ Capital. The company said it will use the funding to scale its international offerings.
“For BioBeats, our vision is to disrupt the way stress is viewed and treated on a global scale,” said Dr. David Plans, founder and chief science officer of BioBeats. “Our approach focuses on challenging the conventional approach to addressing the pandemic of stress and its relation to mental health, cardiovascular disease, and other poor health outcomes; we are truly at a turning point in the digital health revolution, and this latest round of funding will help us achieve remarkable advances for our platform.”
BioBeats uses artificial intelligence (AI) to deliver digital wellness support to consumers and employees. Their primary offering is the BioBase app, which helps users manage their stress while tracking any long-term developments through an in-app dashboard. Additionally, the coaching courses offered by the app educates users on stress-related topics like identifying what triggers personal stress, reports MobiHealthNews.
The company, in the past, was known for its Hear and Now stress app, which monitors heart rates and respiration while providing the user with mindful breathing exercises to ease their anxiety or stress. Other projects from the company included Pulse, an app that generated music based on heart rate, and BioMuse, which built custom music playlists by analyzing physiological metrics.
Earlier this year, BioBeats announced Iain Martin, former managing director at UK greeting card company Moonpig, as its new CEO.
“We’re immensely proud to be supporting the BioBeats team, both because the team is unparalleled in its vision and capability, but also because the company is addressing one of the biggest challenges of our time,” said Lilly Bussmann, principal at Oxford Sciences Innovation. “Mental health is the biggest cause of disability-adjusted life years across any non-communicable disease worldwide. And yet, due to the complexity of the problem at hand, few of the analytics and intervention tools needed for transformative change have emerged. This is where BioBeats comes in and hence why we’re so thrilled to be working with the team.”